Evotec SE and the University Hospital Erlangen today announced a partnership regarding molecular analyses of biospecimens from the German Chronic Kidney Disease (“GCKD”) cohort study. Under the agreement, the research team will make use of Evotec’s proprietary EVOpanOmics and EVOpanHunter platforms to facilitate deep molecular profiling of patient samples. The Evotec platforms combine enhanced throughput proteomics, high-throughput transcriptomics and integrated data analysis. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-and-the-gckd-study-enter-into-strategic-collaboration-to-build-a-unique-molecular-patient-database-6059
Symrise startet dynamisch in das Geschäftsjahr 2021
— Organisches Wachstum von 10,5 % im ersten Quartal — Konzernumsatz steigt auf 950 Mio. € — Ziele 2021 und Mittelfristziele bis 2025 bestätigt Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.symrise.com/de/newsroom/artikel/symrise-startet-dynamisch-in-das-geschaeftsjahr-2021/
Bristol Myers Squibb exercises option to extend targeted protein degradation partnership with Evotec
Evotec SE today announced that Bristol Myers Squibb has decided to exercise their option to extend its partnership with Evotec in the field of targeted protein degradation. Evotec and Bristol Myers Squibb (the successor in interest to Celgene) initiated this strategic drug discovery and development partnership in 2018 with the goal to identify first-in-class drug candidates initially focusing on solid tumours. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/bristol-myers-squibb-exercises-option-to-extend-targeted-protein-degradation-partnership-with-evotec-6057
Chairman of the Supervisory Board of Evotec to resign from office effective as of the end of the Annual General Meeting on 15 June 2021
Evotec SE announces that today the Chairman of the Supervisory Board, Prof. Dr Wolfgang Plischke, has informed the Company of his decision to resign from his office in the Supervisory Board of Evotec SE effective as of the end of the Annual General Meeting on 15 June 2021 due to personal reasons. Prof. Dr Plischke has been serving in the Supervisory Board as Chairman since 2014. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/ad-hoc-releases/p/chairman-of-the-supervisory-board-of-evotec-to-resign-from-office-effective-as-of-the-end-of-the-annual-general-meeting-on-15-june-2021-6055
Symrise stellt Hydrolex™ E vor: multifunktionale Lösung zum Schutz moderner kosmetischer Formulierungen
— Hochwertiger Feuchtigkeitsspender und Emollient, das zum Schutz vor Keimen beiträgt
— Praktisch geruchsfrei, kompatibel mit nahezu allen nachhaltigen Formulierungen
— Ergänzt das bereits existierende Portfolio an Inhaltsstoffen zum Produktschutz von Symrise perfekt Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.symrise.com/de/newsroom/artikel/symrise-stellt-hydrolexTM-e-vor-multifunktionale-loesung-zum-schutz-moderner-kosmetischer-formulierun/
Evotec invests into Oxford Cell Therapy Company "OxVax"
Evotec SE announced today that the Company has invested into OxVax, a new immuno-oncology company based on research from Oxford University, which enables the development of the next generation of cancer vaccines with the potential to overcome the limitations of the current approaches. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-invests-into-oxford-cell-therapy-company-oxvax-6053
Evotec accelerates access to biologic therapeutics with initiation of manufacturing facility in Toulouse
Evotec SE today announced that the Company has initiated the construction of its J.POD® 2 EU biologics manufacturing facility at Evotec’s Campus Curie in Toulouse, France. J.POD® 2 EU, Evotec’s second innovative cGMP biomanufacturing facility, will employ Just – Evotec Biologics’ cutting-edge technology that utilizes small, automated, highly intensified and continuous bioprocessing operations housed inside autonomous cleanrooms. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-accelerates-access-to-biologic-therapeutics-with-initiation-of-manufacturing-facility-in-toulouse-6051
Evotec enters partnership with Kazia Therapeutics for clinical development of EVT801
Evotec SE announced today that the Company has entered into both a licensing and master service agreement with Kazia Therapeutics Limited, an Australian oncology-focused biotechnology company. Under the contract, Evotec will grant Kazia an exclusive worldwide license for research, development and commercialisation of Evotec’s oncology project EVT801. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-enters-partnership-with-kazia-therapeutics-for-clinical-development-of-evt801-6049
Neue Daten bestätigen Wirksamkeit von SymReboot™ L19, der probiotischen Lösung für gesunde Kopfhaut in Shampoos
— Reduziert sichtbar die Trockenheit der Kopfhaut und trockene Schuppen nach nur 2 Wochen
— Beruhigt Rötungen und Juckreiz der Kopfhaut und fördert gesundes Kopfhaut-Mikrobiom
— Kombiniert Innovationen aus zwei Schlüsselbereichen: Probiotika und empfindliche Haut
— Eröffnet neue Optionen für Kosmetikhersteller mit probiotischen Inhaltsstoffen Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.symrise.com/de/newsroom/artikel/neue-daten-bestaetigen-wirksamkeit-von-symrebootTM-l19-der-probiotischen-loesung-fuer-gesunde-kopfhaut/
Evotec launches “beLAB2122”, translating academic innovation from leading German life science region in collaboration with Bristol Myers Squibb
Evotec SE announced today that the Company has launched beLAB2122, a translational $ 20 million BRIDGE in collaboration with Bristol-Myers Squibb Company. beLAB2122 brings together leading academic institutions from the Rhine-Main-Neckar region of Germany with the goal of efficiently advancing first-in-class therapeutic options across all therapeutic areas and formats into investable drug discovery and early development projects. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-launches-belab2122-translating-academic-innovation-from-leading-german-life-science-region-in-collaboration-with-bristol-myers-squibb-6047